IMBiologics Corp.
KKRX:49328014,530.00
KRW
+210.00
(+1.47%)
ISIN
KR7493280002
Return %
Stock
S&P 500
1Y
- -
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Kyung-Sik Ha
- Full Time Employees
- 41
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Suwon-si South Korea
- IPO Date
- Mar 20, 2026
- Website
- imbiologics.com
- Similar Companies
- Business
- IMBiologics Corp. is a South Korea-based clinical-stage biopharmaceutical company that specializes in the research, development, and commercialization of next-generation antibody therapeutics for autoimmune disorders, inflammatory conditions, and immuno-oncology indications. Founded in 2020 and headquartered in Seoul, South Korea, the company leverages proprietary antibody discovery and engineering platforms to develop targeted biologics. Its core therapeutic pipeline comprises IMB-101, a clinical-stage bispecific antibody targeting OX40 ligand (OX40L) and tumor necrosis factor-alpha (TNF-alpha) indicated for rheumatoid arthritis, inflammatory bowel disease, and related autoimmune conditions; IMB-102, an OX40L-targeting monoclonal antibody candidate indicated for atopic dermatitis, asthma, and allergic disorders; IMB-201, an investigational bispecific antibody designed for solid tumor immuno-oncology applications; and IMB-301, a multivalent antibody candidate engineered to modulate tumor microenvironments. The company also develops proprietary platform technologies, including the ePENDy multivalent antibody engineering platform and bispecific antibody discovery modules, which enable the design of multispecific therapeutic proteins with enhanced avidity and safety profiles. In recent operational developments, IMBiologics Corp. substantially broadened its global commercialization network through major cross-border licensing transactions, including an exclusive out-licensing agreement with United States-based Navigator Medicines for the development and commercial rights to IMB-101 and IMB-102 across global territories outside of Asia in a transaction valued at up to 944 million USD; a strategic licensing agreement with China-based Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. for exclusive development and commercial rights to IMB-101 and IMB-102 in Greater China valued at up to 315.5 million USD; and the advancement of global Phase 1 clinical trials for IMB-101 alongside its public listing on the Korea Exchange under ticker 493280 to accelerate pipeline progression and platform validation across international markets.